Perfluorocarbons having a short dwell time in the liver

Area of Science:

• Biomedical Engineering
• Toxicology
• Organic Chemistry

Background:

• Perfluorinated organic liquids are effective oxygen and carbon dioxide solvents.
• Previous perfluorocarbon emulsions accumulate in the liver and spleen, limiting their use as artificial blood.
• This accumulation poses challenges for long-term biomedical applications.

Purpose of the Study:

• To investigate a new family of perfluorocarbons for potential use as artificial blood.
• To evaluate the pharmacokinetic profile and safety of these novel perfluorocarbons.
• To determine if these compounds can overcome the limitations of previous perfluorocarbon emulsions.

Main Methods:

• Intravenous infusion of a novel perfluorocarbon family in animal models.
• Monitoring of perfluorocarbon distribution and deposition in organs.
• Assessment of excretion pathways (lungs, skin) and animal health.

Main Results:

• The newly discovered perfluorocarbons are initially deposited in the liver after intravenous infusion.
• These compounds are subsequently excreted from the liver via the lungs and skin.
• Excretion occurs within days without apparent harm to the animal.

Conclusions:

• This new family of perfluorocarbons demonstrates a favorable pharmacokinetic profile for biomedical applications.
• Their safe and rapid excretion suggests a reduced risk of long-term organ accumulation.
• These perfluorocarbons show promise as improved artificial blood substitutes or organ perfusion media.